You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameErgonovine
Accession NumberDB01253
TypeSmall Molecule
GroupsApproved
DescriptionAn ergot alkaloid with uterine and vascular smooth muscle contractile properties. [PubChem]
Structure
Thumb
Synonyms
(6AR,9R)-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
[8beta(S)]-9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide
9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide
9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide
D-Lysergic acid 1-hydroxymethylethylamide
D-Lysergic acid-L-propanolamide
Ergobasine
Ergometrina
Ergometrine
Ergometrinum
Ergonovine
Ergotrate maleate
N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide
N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ergonovine Maleate Injectionsolution0.25 mgintramuscular; intravenousMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Ergonovine Maleate Injectionsolution0.25 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2016-02-19Not applicableCanada
Ergonovine Maleate Injectionsolution.25 mgintramuscular; intravenousHospira Healthcare Corporation1981-12-31Not applicableCanada
Ergonovine Maleate Injection USP, 0.25mg/mlsolution0.25 mgintramuscular; intravenousAlveda Pharmaceuticals Inc2010-06-01Not applicableCanada
Ergotrate Maleate Tablet 1572 0.2mgtablet.2 mgoralEli Lilly Canada Inc1939-12-311998-08-04Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ErgotrateNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Ergonovine maleate
ThumbNot applicableDBSALT001151
Categories
UNIIWH41D8433D
CAS number60-79-7
WeightAverage: 325.4048
Monoisotopic: 325.179026995
Chemical FormulaC19H23N3O2
InChI KeyInChIKey=WVVSZNPYNCNODU-XTQGRXLLSA-N
InChI
InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
IUPAC Name
(4R,7R)-N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[[email protected]](CN2C)C(=O)N[C@@H](C)CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassErgoline and derivatives
Sub ClassLysergic acids and derivatives
Direct ParentLysergamides
Alternative Parents
Substituents
  • Lysergic acid amide
  • Indoloquinoline
  • Benzoquinoline
  • Quinoline-3-carboxamide
  • Pyrroloquinoline
  • Quinoline
  • Isoindole or derivatives
  • Indole or derivatives
  • Indole
  • Aralkylamine
  • Tetrahydropyridine
  • Benzenoid
  • Heteroaromatic compound
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
PharmacodynamicsErgonovine belongs to the group of medicines known as ergot alkaloids. These medicines are usually given to stop excessive bleeding that sometimes occurs after abortion or a baby is delivered. They work by causing the muscle of the uterus to contract.
Mechanism of actionErgonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and serotonin receptors and inhibition of endothelial-derived relaxation factor release. It is a less potent vasoconstrictor than ergotamine. As a diagnostic aid (coronary vasospasm), ergonovine causes vasoconstriction of coronary arteries.
Related Articles
AbsorptionAbsorption is rapid and complete after oral or intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationThought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)
Half lifet1/2 α=10 minutes; t1/2 β=2 hours
ClearanceNot Available
ToxicityThe principal symptoms of overdose are convulsions and gangrene. Other symptoms include bradycardia, confusion, diarrhoea, dizziness, dyspnoea, drowsiness, fast and/or weak pulse, miosis, hypercoagulability, loss of consciousness, nausea and vomiting, numbness and coldness of the extremities, pain in the chest, peripheral vasoconstriction, respiratory depression, rise or fall in blood pressure, severe cramping of the uterus, tachycardia, tingling, and unusual thirst.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6971
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8385
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.7295
CYP450 2C9 substrateNon-substrate0.8097
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6814
CYP450 1A2 substrateNon-inhibitor0.7284
CYP450 2C9 inhibitorNon-inhibitor0.9116
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9228
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9236
Ames testNon AMES toxic0.5743
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.8714
Rat acute toxicity3.3967 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.954
hERG inhibition (predictor II)Inhibitor0.5624
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Solutionintramuscular; intravenous.25 mg
Solutionintramuscular; intravenous0.25 mg
Tabletoral.2 mg
Prices
Unit descriptionCostUnit
Ergonovine maleate 100% powder676.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point162 °CPhysProp
water solubility2.68 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP0.9Not Available
pKa6.8MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.321 mg/mLALOGPS
logP1.53ALOGPS
logP1.07ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)15ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.05 m3·mol-1ChemAxon
Polarizability36.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesG02AB03
AHFS Codes
  • 76:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Ergonovine can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Ergonovine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
AcebutololAcebutolol may increase the vasoconstricting activities of Ergonovine.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Ergonovine.
AcepromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Ergonovine.
AcetophenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Ergonovine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ergonovine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ergonovine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ergonovine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergonovine.
AlmotriptanErgonovine may increase the vasoconstricting activities of Almotriptan.
AlogliptinThe serum concentration of Ergonovine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Ergonovine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprenololAlprenolol may increase the vasoconstricting activities of Ergonovine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Ergonovine.
AmiodaroneThe metabolism of Ergonovine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ergonovine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergonovine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.
AmperozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amperozide.
AmprenavirThe serum concentration of Ergonovine can be increased when it is combined with Amprenavir.
Antithrombin III humanThe serum concentration of Ergonovine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.
ApomorphineErgonovine may increase the vasoconstricting activities of Apomorphine.
AprepitantThe serum concentration of Ergonovine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Ergonovine can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Ergonovine can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.
ArotinololArotinolol may increase the vasoconstricting activities of Ergonovine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ergonovine.
AsenapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Asenapine.
AsunaprevirThe serum concentration of Ergonovine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Ergonovine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the vasoconstricting activities of Ergonovine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Ergonovine.
AtomoxetineThe metabolism of Ergonovine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ergonovine.
AzaperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azaperone.
BatimastatThe serum concentration of Ergonovine can be increased when it is combined with Batimastat.
BefunololBefunolol may increase the vasoconstricting activities of Ergonovine.
BenazeprilThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Ergonovine can be increased when it is combined with Benzamidine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ergonovine.
BetaxololBetaxolol may increase the vasoconstricting activities of Ergonovine.
BevantololBevantolol may increase the vasoconstricting activities of Ergonovine.
BexaroteneThe serum concentration of Ergonovine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bifeprunox.
BisoprololBisoprolol may increase the vasoconstricting activities of Ergonovine.
BivalirudinThe serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Ergonovine can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the vasoconstricting activities of Ergonovine.
BortezomibThe metabolism of Ergonovine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ergonovine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ergonovine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Brexpiprazole.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergonovine.
BromocriptineErgonovine may increase the vasoconstricting activities of Bromocriptine.
BufuralolBufuralol may increase the vasoconstricting activities of Ergonovine.
BupranololBupranolol may increase the vasoconstricting activities of Ergonovine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ergonovine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergonovine.
CabergolineErgonovine may increase the vasoconstricting activities of Cabergoline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Ergonovine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ergonovine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ergonovine.
CandoxatrilThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Ergonovine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Ergonovine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Ergonovine.
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergonovine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ergonovine.
CariprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cariprazine.
CarteololCarteolol may increase the vasoconstricting activities of Ergonovine.
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergonovine.
CeliprololCeliprolol may increase the vasoconstricting activities of Ergonovine.
CeritinibThe serum concentration of Ergonovine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergonovine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.
ChymostatinThe serum concentration of Ergonovine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Ergonovine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ergonovine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ergonovine.
CirazolineErgonovine may increase the hypertensive activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ergonovine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ergonovine.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.
ClarithromycinThe metabolism of Ergonovine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ergonovine.
ClemastineThe metabolism of Ergonovine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ergonovine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Ergonovine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ergonovine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Ergonovine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ergonovine.
ClotrimazoleThe metabolism of Ergonovine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clozapine.
CobicistatThe metabolism of Ergonovine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ergonovine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ergonovine.
ConivaptanThe serum concentration of Ergonovine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Ergonovine.
CrizotinibThe metabolism of Ergonovine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ergonovine.
CyamemazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cyamemazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.
CyclosporineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ergonovine.
Dabigatran etexilateThe serum concentration of Ergonovine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Ergonovine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Ergonovine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ergonovine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ergonovine.
DapiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergonovine.
DarunavirThe serum concentration of Ergonovine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ergonovine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Ergonovine.
DeferasiroxThe serum concentration of Ergonovine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ergonovine can be decreased when combined with Delavirdine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ergonovine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Ergonovine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ergonovine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergonovine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ergonovine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ergonovine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ergonovine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ergonovine.
DihydroergotamineThe metabolism of Ergonovine can be decreased when combined with Dihydroergotamine.
DihydroergotamineErgonovine may increase the vasoconstricting activities of Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Ergonovine.
DiltiazemThe metabolism of Ergonovine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Ergonovine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Ergonovine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ergonovine.
DolasetronDolasetron may increase the serotonergic activities of Ergonovine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ergonovine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ergonovine.
DoxycyclineThe metabolism of Ergonovine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Ergonovine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.
EcabetThe serum concentration of Ergonovine can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Ergonovine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Ergonovine can be decreased when it is combined with Efavirenz.
ElafinThe serum concentration of Ergonovine can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergonovine.
EletriptanErgonovine may increase the vasoconstricting activities of Eletriptan.
EnalaprilThe serum concentration of Ergonovine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Ergonovine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Ergonovine can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ergonovine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergonovine.
ErgotamineErgonovine may increase the hypertensive activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ergonovine.
ErythromycinThe metabolism of Ergonovine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ergonovine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.
Eslicarbazepine acetateThe serum concentration of Ergonovine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the vasoconstricting activities of Ergonovine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ergonovine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Ergonovine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Ergonovine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Ergonovine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ergonovine.
EtravirineThe serum concentration of Ergonovine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ergonovine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ergonovine.
FencamfamineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ergonovine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ergonovine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ergonovine.
FluconazoleThe metabolism of Ergonovine can be decreased when combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.
FlupentixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ergonovine.
FluvoxamineThe metabolism of Ergonovine can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Ergonovine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ergonovine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Ergonovine can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ergonovine.
FrovatriptanErgonovine may increase the vasoconstricting activities of Frovatriptan.
Fusidic AcidThe serum concentration of Ergonovine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ergonovine.
GeldanamycinThe serum concentration of Ergonovine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Ergonovine.
GM6001The serum concentration of Ergonovine can be increased when it is combined with GM6001.
GranisetronGranisetron may increase the serotonergic activities of Ergonovine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ergonovine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ergonovine.
HaloperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.
HirulogThe serum concentration of Ergonovine can be increased when it is combined with Hirulog.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ergonovine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Ergonovine.
IdelalisibThe serum concentration of Ergonovine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.
ImatinibThe metabolism of Ergonovine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Ergonovine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ergonovine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ergonovine.
IndenololIndenolol may increase the vasoconstricting activities of Ergonovine.
IndinavirThe serum concentration of Ergonovine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Ergonovine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ergonovine.
IsavuconazoniumThe metabolism of Ergonovine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ergonovine.
IsoflurophateThe serum concentration of Ergonovine can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Ergonovine can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Ergonovine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Ergonovine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ergonovine.
IxazomibThe serum concentration of Ergonovine can be increased when it is combined with Ixazomib.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ergonovine.
KetoconazoleThe serum concentration of Ergonovine can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the vasoconstricting activities of Ergonovine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ergonovine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Ergonovine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ergonovine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ergonovine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ergonovine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ergonovine.
LepirudinThe serum concentration of Ergonovine can be increased when it is combined with Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ergonovine.
LevobunololLevobunolol may increase the vasoconstricting activities of Ergonovine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ergonovine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ergonovine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Ergonovine.
LinagliptinThe serum concentration of Ergonovine can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergonovine.
LisinoprilThe serum concentration of Ergonovine can be increased when it is combined with Lisinopril.
LisurideErgonovine may increase the vasoconstricting activities of Lisuride.
LithiumThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ergonovine.
LopinavirThe serum concentration of Ergonovine can be increased when it is combined with Lopinavir.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergonovine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Ergonovine.
LovastatinThe metabolism of Ergonovine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loxapine.
Lu AA21004Ergonovine may increase the vasoconstricting activities of Lu AA21004.
LuliconazoleThe serum concentration of Ergonovine can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Ergonovine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.
MelperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Melperone.
MephentermineErgonovine may increase the hypertensive activities of Mephentermine.
MesoridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.
MetaraminolErgonovine may increase the hypertensive activities of Metaraminol.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergonovine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ergonovine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.
MethoxamineErgonovine may increase the hypertensive activities of Methoxamine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ergonovine.
MetipranololMetipranolol may increase the vasoconstricting activities of Ergonovine.
MetoclopramideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.
MetoprololMetoprolol may increase the vasoconstricting activities of Ergonovine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Ergonovine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ergonovine.
MidodrineErgonovine may increase the hypertensive activities of Midodrine.
MifepristoneThe metabolism of Ergonovine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ergonovine is combined with Milnacipran.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ergonovine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergonovine.
MitotaneThe serum concentration of Ergonovine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ergonovine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ergonovine.
ModafinilThe serum concentration of Ergonovine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Ergonovine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergonovine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergonovine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololNadolol may increase the vasoconstricting activities of Ergonovine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Ergonovine.
NafcillinThe serum concentration of Ergonovine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ergonovine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Ergonovine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ergonovine.
NaratriptanErgonovine may increase the vasoconstricting activities of Naratriptan.
NCX 4016The serum concentration of Ergonovine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Ergonovine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nefazodone.
NelfinavirThe serum concentration of Ergonovine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Ergonovine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ergonovine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Ergonovine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ergonovine.
NilotinibThe metabolism of Ergonovine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ergonovine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ergonovine.
NitroglycerinErgonovine may decrease the vasodilatory activities of Nitroglycerin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ergonovine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergonovine.
OlanzapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine.
OlaparibThe metabolism of Ergonovine can be decreased when combined with Olaparib.
OmapatrilatThe serum concentration of Ergonovine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ergonovine.
OndansetronThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Ergonovine.
OsanetantThe risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.
OsimertinibThe serum concentration of Ergonovine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Ergonovine can be increased when it is combined with Otamixaban.
OxprenololOxprenolol may increase the vasoconstricting activities of Ergonovine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ergonovine.
PalbociclibThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Ergonovine.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ergonovine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.
PenbutololPenbutolol may increase the vasoconstricting activities of Ergonovine.
PentobarbitalThe metabolism of Ergonovine can be increased when combined with Pentobarbital.
PergolideErgonovine may increase the vasoconstricting activities of Pergolide.
PerindoprilThe serum concentration of Ergonovine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergonovine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergonovine.
PhenobarbitalThe metabolism of Ergonovine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Ergonovine.
PhenylephrineErgonovine may increase the hypertensive activities of Phenylephrine.
PhenytoinThe metabolism of Ergonovine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Ergonovine.
PhosphoramidonThe serum concentration of Ergonovine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pimozide.
PindololPindolol may increase the vasoconstricting activities of Ergonovine.
PipamperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergonovine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ergonovine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ergonovine.
PosaconazoleThe serum concentration of Ergonovine can be increased when it is combined with Posaconazole.
PractololPractolol may increase the vasoconstricting activities of Ergonovine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergonovine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Ergonovine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ergonovine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ergonovine.
PrimidoneThe metabolism of Ergonovine can be increased when combined with Primidone.
PrinomastatThe serum concentration of Ergonovine can be increased when it is combined with Prinomastat.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ergonovine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Ergonovine.
PromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ergonovine.
PropericiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propericiazine.
PropranololPropranolol may increase the vasoconstricting activities of Ergonovine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Ergonovine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ergonovine.
PRX-00023Ergonovine may increase the vasoconstricting activities of PRX-00023.
QuetiapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quetiapine.
QuinaprilThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ergonovine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Ergonovine.
RamiprilThe serum concentration of Ergonovine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ergonovine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ergonovine.
RanolazineThe metabolism of Ergonovine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.
RemikirenThe serum concentration of Ergonovine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Reserpine.
RifabutinThe metabolism of Ergonovine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ergonovine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Ergonovine.
RifapentineThe metabolism of Ergonovine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ergonovine.
RisperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Risperidone.
RitonavirThe serum concentration of Ergonovine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ergonovine.
RizatriptanErgonovine may increase the vasoconstricting activities of Rizatriptan.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ergonovine.
RopiniroleErgonovine may increase the vasoconstricting activities of Ropinirole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Ergonovine.
SaquinavirThe serum concentration of Ergonovine can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Ergonovine can be increased when it is combined with Saxagliptin.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergonovine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Ergonovine.
SertindoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ergonovine.
SildenafilThe metabolism of Ergonovine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.
SiltuximabThe serum concentration of Ergonovine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ergonovine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Ergonovine can be increased when it is combined with Sitagliptin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ergonovine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ergonovine.
SotalolSotalol may increase the vasoconstricting activities of Ergonovine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ergonovine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ergonovine.
SpiraprilThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Ergonovine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ergonovine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Ergonovine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ergonovine.
SumatriptanErgonovine may increase the vasoconstricting activities of Sumatriptan.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Ergonovine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ergonovine.
TapentadolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ergonovine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ergonovine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergonovine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Ergonovine can be increased when it is combined with Telaprevir.
TelithromycinThe metabolism of Ergonovine can be decreased when combined with Telithromycin.
TemocaprilThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ergonovine.
ThioproperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.
ThiorphanThe serum concentration of Ergonovine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ergonovine.
TiclopidineThe metabolism of Ergonovine can be decreased when combined with Ticlopidine.
TimololTimolol may increase the vasoconstricting activities of Ergonovine.
TimololThe serum concentration of Timolol can be increased when it is combined with Ergonovine.
TipranavirThe serum concentration of Ergonovine can be increased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ergonovine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ergonovine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Ergonovine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.
TrandolaprilThe serum concentration of Ergonovine can be increased when it is combined with Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ergonovine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergonovine.
UbenimexThe serum concentration of Ergonovine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Ergonovine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ergonovine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ergonovine.
VenlafaxineThe metabolism of Ergonovine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ergonovine.
VerapamilThe metabolism of Ergonovine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ergonovine.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergonovine.
VilazodoneErgonovine may increase the vasoconstricting activities of Vilazodone.
VildagliptinThe serum concentration of Ergonovine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ergonovine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ergonovine.
VoriconazoleThe serum concentration of Ergonovine can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ergonovine.
VortioxetineErgonovine may increase the vasoconstricting activities of Vortioxetine.
XimelagatranThe serum concentration of Ergonovine can be increased when it is combined with Ximelagatran.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Ergonovine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Ergonovine can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergonovine.
ZolmitriptanErgonovine may increase the vasoconstricting activities of Zolmitriptan.
ZotepineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Gibson A, Carvajal A: Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. [PubMed:2897449 ]
  2. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9. [PubMed:12583687 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113 ]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
Comments
comments powered by Disqus
Drug created on April 04, 2007 16:45 / Updated on August 17, 2016 12:23